Adicet Bio Stock Net Income
| ACET Stock | USD 1.45 0.03 2.03% |
Adicet Bio fundamentals help investors to digest information that contributes to Adicet Bio's financial success or failures. It also enables traders to predict the movement of Adicet Stock. The fundamental analysis module provides a way to measure Adicet Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adicet Bio stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -142.7 M | -135.5 M | |
| Net Loss | -142.7 M | -135.5 M | |
| Net Loss | (3.31) | (3.15) | |
| Net Income Per E B T | 0.86 | 0.61 |
Adicet | Net Income |
Adicet Bio Company Net Income Analysis
Adicet Bio's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Adicet Bio Net Income | (142.66 M) |
Most of Adicet Bio's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adicet Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adicet Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Adicet Bio is extremely important. It helps to project a fair market value of Adicet Stock properly, considering its historical fundamentals such as Net Income. Since Adicet Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adicet Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adicet Bio's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Adicet Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Adicet Bio reported net income of (142.66 Million). This is 141.8% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 124.98% higher than that of the company.
Adicet Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adicet Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adicet Bio could also be used in its relative valuation, which is a method of valuing Adicet Bio by comparing valuation metrics of similar companies.Adicet Bio is currently under evaluation in net income category among its peers.
Adicet Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adicet Bio from analyzing Adicet Bio's financial statements. These drivers represent accounts that assess Adicet Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adicet Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 156.2M | 102.8M | 541.4M | 367.3M | 81.4M | 77.3M | |
| Enterprise Value | 259.6M | 40.2M | 284.8M | 130.6M | (57.4M) | (54.6M) |
Adicet Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Adicet Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Adicet Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adicet Bio's value.| Shares | Rtw Investments, Llc | 2024-06-30 | 1.1 M | Blackrock Inc | 2024-06-30 | 1 M | D. E. Shaw & Co Lp | 2024-06-30 | 836 K | Cowen And Company, Llc | 2024-06-30 | 801.3 K | Octagon Capital Advisors Lp | 2024-06-30 | 767.8 K | Geode Capital Management, Llc | 2024-06-30 | 671 K | Alyeska Investment Group, L.p. | 2024-06-30 | 655.7 K | Two Sigma Investments Llc | 2024-06-30 | 631.1 K | Stonepine Capital Management Llc | 2024-06-30 | 609.4 K | Orbimed Advisors, Llc | 2024-06-30 | 11.4 M | Tang Capital Management Llc | 2024-06-30 | 8.2 M |
Adicet Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (82.98 M) | ||||
| Shares Outstanding | 82.4 M | ||||
| Shares Owned By Insiders | 1.59 % | ||||
| Shares Owned By Institutions | 76.37 % | ||||
| Number Of Shares Shorted | 3.72 M | ||||
| Price To Earning | 36.84 X | ||||
| Price To Book | 0.52 X | ||||
| Price To Sales | 9.72 X | ||||
| Gross Profit | 24.99 M | ||||
| EBITDA | (126.48 M) | ||||
| Net Income | (142.66 M) | ||||
| Cash And Equivalents | 260.64 M | ||||
| Cash Per Share | 6.11 X | ||||
| Total Debt | 20.92 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 16.10 X | ||||
| Book Value Per Share | 2.85 X | ||||
| Cash Flow From Operations | (93.72 M) | ||||
| Short Ratio | 9.15 X | ||||
| Earnings Per Share | (2.52) X | ||||
| Price To Earnings To Growth | 0.82 X | ||||
| Target Price | 6.4 | ||||
| Number Of Employees | 143 | ||||
| Beta | 1.69 | ||||
| Market Capitalization | 119.48 M | ||||
| Total Asset | 207.29 M | ||||
| Retained Earnings | (380.77 M) | ||||
| Working Capital | 142.99 M | ||||
| Current Asset | 352.66 M | ||||
| Current Liabilities | 98.91 M | ||||
| Five Year Return | 3.23 % | ||||
| Net Asset | 207.29 M |
About Adicet Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adicet Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adicet Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adicet Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.